

## **PREZISTA® (darunavir) Concomitant Use of PREZISTA with Paxlovid™ (nirmatrelvir tablets and ritonavir tablets)**

### **SUMMARY**

- Currently, there are no published data evaluating the concomitant use of PREZISTA and Paxlovid.<sup>1,2</sup>
- According to the Paxlovid Prescribing Information, patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated.<sup>2</sup>

### **CLINICAL DATA**

- There are no published data evaluating the concomitant use of PREZISTA and Paxlovid, which is nirmatrelvir tablets co-packaged with ritonavir (100 mg) tablets.<sup>1,2</sup>
- According to the PREZISTA Prescribing Information, PREZISTA must be co-administered with ritonavir.<sup>1</sup>
- Use of PREZISTA/r in combination with other medications metabolized by CYP3A and/or that inhibit CYP3A may increase plasma concentrations of PREZISTA/r and/or the concomitant medications. These interactions may lead to clinically significant adverse reactions.<sup>1</sup>
- According to the Paxlovid Prescribing Information, patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased Paxlovid or protease inhibitor adverse events.<sup>2</sup>

### **GUIDANCE DOCUMENTS**

There are several resources that provide guidance for managing potential DDIs with ritonavir-boosted nirmatrelvir. These resources advise providers to exercise clinical judgement to assess the risks and benefits of therapy when managing patients on a case-by-case basis.

- Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. Last Updated: July 21, 2023. In: COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: <https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/>
- Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group, University of Waterloo School of Pharmacy. Nirmatrelvir/Ritonavir (Paxlovid): What prescribers and pharmacists need to know. *Ontario COVID-19 Science Advisory Table*. 2022;3(58). <https://doi.org/10.47326/ocsat.2022.03.58.3.0>
- University of Liverpool. COVID-19 Drug Interactions. Available at: <https://www.covid19-druginteractions.org/checker>, Accessed 27 October 2023.
- Infectious Disease Society of America. Management of Drug Interactions with Nirmatrelvir/Ritonavir (Paxlovid): Resource for Clinicians. Last Updated: May 6, 2022. Available at: <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/management-of-drug-interactions-with-nirmatrelvirritonavir-paxlovid/>

### **LITERATURE SEARCH**

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 27 October 2023.

### **REFERENCES**

1. PREZISTA (darunavir) [Prescribing Information]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP; <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/PREZISTA-pi.pdf>.

2. PAXLOVID (nirmatrelvir tablets and ritonavir tablets) [Prescribing Information]. New York: Pfizer Labs, Division of Pfizer, Inc; <https://labeling.pfizer.com/ShowLabeling.aspx?id=19599>.